Differences in the cellular immune response during and after treatment of Sudanese patients with post-kala-azar dermal leishmaniasis, and possible implications for outcome

by Torres A, Younis BM, Alamin M, Tesema S, Bernardo L, Solana JC, Moreno J, Mustafa A-a, Alves F, Mudawi Musa A, Carrillo E. Journal of Epidemiology and Global Health 2024. doi: 10.1007/s44197-024-00270-0

Summary: Little is known about the cellular immune response for post-kala-azar dermal leishmaniasis (PKDL). The authors of this manuscript report changes in the cellular immune response of participants in a phase II clinical trial of two treatments for patients with PKDL in Sudan. The Th1/Th2/Th17 response seen with paromomycin + miltefosine was associated with a higher cure rate (98.2%) than the Th1/Th2 response seen with liposomal amphotericin B + miltefosine (80%). Patients with low IFN-γ, TNF and IL-1β before treatment were more likely to relapse if treated with liposomal amphotericin B + miltefosine than with paromomycin + miltefosine. Determining IFN-γ, TNF and IL-10 levels prior to treatment could help predict which patients might be at higher risk of poor treatment response.

The post Differences in the cellular immune response during and after treatment of Sudanese patients with post-kala-azar dermal leishmaniasis, and possible implications for outcome first appeared on DNDi.